Evidence map›Paper›PMID 40295723›Full record

ArticleScientific reports2025

Author Correction: Full-length RNA-Seq of the RHOH gene in human B cells reveals new exons and splicing patterns.

Frédéric Leprêtre, Jean-Pascal Meneboo, Céline Villenet, Laure Delestré, Bruno Quesnel, Carl Simon Shelley, Martin Figeac, Sylvie Galiègue-Zouitina

Abstract readPublished Erratum
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Frédéric LeprêtreUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41-UAR 2014-PLBS, 59000, Lille, France. Frederic.lepretre@univ-lille.fr.ORCID http://orcid.org/0000-0002-5249-3930
Jean-Pascal MenebooUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41-UAR 2014-PLBS, 59000, Lille, France.ORCID http://orcid.org/0000-0001-8272-3496
Céline VillenetUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41-UAR 2014-PLBS, 59000, Lille, France.
Laure DelestréInserm U1170, 94800, Villejuif, France.ORCID http://orcid.org/0000-0001-6243-3547
Bruno QuesnelCHU Lille, UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, 59000, Lille, France.ORCID http://orcid.org/0000-0002-6563-2709
Carl Simon ShelleyLeukemia Therapeutics, LLC, Hull, MA, 02045, USA.ORCID http://orcid.org/0000-0001-5209-3577
Martin FigeacUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41-UAR 2014-PLBS, 59000, Lille, France.ORCID http://orcid.org/0000-0001-8523-3708
Sylvie Galiègue-ZouitinaInstitut pour la Recherche sur le Cancer de Lille, Place de Verdun, 59054, Lille, France. Sylvie.zouitina@outlook.fr.ORCID http://orcid.org/0000-0001-5148-5691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40295723
PMCPMC12037778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.